Upstream Medical Technologies
ShutdownWebsite unreachable since Oct 21, 2026
Upstream Medical Technologies is developing Marker C, a patented blood test that identifies patients with unstable angina, a precursor to heart attacks, within hours of their emergency room presentation. This technology enables more accurate triage of chest pain patients, potentially increasing the efficiency of emergency departments by categorizing 10-35% more patients at risk for acute coronary syndrome.
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$12.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$9.8M across 4 disclosed rounds
EAEIICKANZ$2M · Undisclosed
Announced May 2023
Disclosed cumulative: $9.8M
Reported total $12.6M
Incomplete round history. $2.8M of the $12.6M reported total isn’t matched to a known round.
Founders
Founder details are not available yet.
Product
Problem
Emergency room physicians lack a rapid, objective diagnostic tool to accurately triage patients presenting with chest pain, particularly those in the "troponin grey-zone," leading to uncertainty in risk stratification for acute coronary syndrome. Existing cardiac biomarkers often fail to provide timely and definitive results, potentially delaying appropriate intervention for patients with unstable angina.
Solution
Upstream Medical Technologies is developing Marker C, a patented blood test designed to rapidly identify patients with unstable angina, a precursor to heart attacks, within hours of their arrival in the emergency department. Marker C aims to improve the accuracy of chest pain triage by categorizing a significant portion of patients at risk for acute coronary syndrome who might otherwise be missed. By providing physicians with a rapid and objective diagnostic tool, Marker C enables more informed and timely clinical decision-making, potentially reducing morbidity and mortality associated with heart attacks. The test assists emergency rooms and cardiac testing clinics to more accurately identify patients suffering acute coronary syndrome.
Target Audience
The primary target audience includes emergency room physicians, cardiologists, and cardiac testing clinics seeking to improve the speed and accuracy of chest pain triage and risk stratification for acute coronary syndrome.
Features
- Patented biomarker diagnostic blood test for unstable angina
- Rapid results available within hours of emergency room presentation
- Designed to identify patients in the "troponin grey-zone"
- Aims to improve triage accuracy for chest pain patients
- Potential to categorize 10-35% more patients at risk for acute coronary syndrome